Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 14, 2025, discloses a material definitive agreement entered into by Jaguar Health, Inc. on November 12, 2025. The Company, a Delaware corporation trading on the Nasdaq Capital Market, executed a secured note financing transaction to raise capital and manage existing debt obligations.
Key Financial Metrics and Transaction Details
- Debt Instrument: Secured Promissory Note with an original principal amount of $10,810,000.
- Net Proceeds: $2,000,000 paid directly to the Company; $8,000,000 deposited into a restricted Deposit Account.
- Interest Rate: 8.00% per annum.
- Maturity: 36 months from issuance (November 12, 2025).
- Discount and Fees: Includes an $800,000 original issue discount and $10,000 in transaction costs, both included in the principal balance.
- Collateral: Secured by a Deposit Account Control Agreement (DACA), a guaranty from a wholly-owned subsidiary (JAGX Holdings, LLC), and a pledge of all membership interests in the subsidiary.
- Default Interest: Increases to the lesser of 18% per annum or the maximum rate permitted by law upon an Event of Default.
Material Changes and Covenants
The filing details significant restrictions on the Company's financial flexibility compared to prior periods:
- Restricted Cash: $8,000,000 is held in a restricted account. Withdrawals are permitted only if funds exceed the "Collateral Requirement," which starts at $8,000,000 and decreases as unsecured obligations are repaid.
- Mandatory Prepayments: The Company must prepay the Note upon certain IP Transactions, equal to the lesser of the outstanding balance or 25% of upfront licensing fees received.
- Redemption Rights: Beginning 12 months after issuance, the Lender may redeem up to $600,000 plus accrued interest per calendar month.
- Trigger Events: The Lender may increase the outstanding balance by 15% for Major Trigger Events or 5% for Minor Trigger Events (up to three times each). Failure to cure within five trading days results in an automatic Event of Default.
- Issuance Restrictions: The Company cannot make "Restricted Issuances" (including variable rate transactions or convertible securities with price resets) without Lender consent.
Guidance, Outlook, and Use of Proceeds
The filing does not provide forward-looking financial guidance or management commentary regarding future revenue or earnings. The stated use of proceeds is at the Company's sole discretion, specifically including the repayment of all or part of the outstanding balances of 6% convertible promissory notes issued on June 24, 2025 (the "Bridge Notes").
Investor Verification Checklist
- Verify the exact outstanding balance of the "Bridge Notes" issued on June 24, 2025, to determine the immediate impact of the new proceeds.
- Review the definitions of "Major Trigger Event" and "Minor Trigger Event" in the Note to assess the risk of balance increases.
- Confirm the current status of the $8,000,000 restricted Deposit Account and any potential for early release of funds based on the Collateral Requirement formula.
- Examine the Company's existing unsecured debt obligations to calculate the timeline for reducing the Collateral Requirement.
- Assess the impact of the mandatory prepayment clause on future IP licensing deals.